Screener
Aurinia Pharmaceuticals AUPH Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Aurinia Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's debt-to-equity?
- Aurinia Pharmaceuticals (AUPH) reported debt-to-equity of 0.1× in Q2 2026.
- How has Aurinia Pharmaceuticals's debt-to-equity changed year-over-year?
- Aurinia Pharmaceuticals's debt-to-equity decreased by 55.1% year-over-year, from 0.3× to 0.1×.
- What is the long-term trend for Aurinia Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's debt-to-equity has grown at a 50.1% compound annual growth rate (CAGR), from 0× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Aurinia Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude